Replies to post #191727 on Biotech Values

[DewDiligence]

ABBV/ENTA also plan to apply for GT2 Japanese approval by year-end 2015. The submission will be based on the GIFT-2 study (#msg-95444387).

[dewophile]

From the release it sounds like the first trial only enrolled non-ciorrhotics w high baseline VL, so the 95% SVR has to be taken in that context. Not sure about the randomized portion, but the 98% here helps compete w GILD (GILD had 100% SVR in a somewhat smaller trial)
I don't think the cirrhotic data is competitive w GILD though